METHOD FOR ASSESSING RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-VEGF THERAPY Russian patent published in 2024 - IPC A61B5/153 G01N33/49 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology. At the prehospital stage, the peripheral blood is sampled before the beginning of the drug therapy. Blood serum is recovered with subsequent aliquoting and determination of cytokine concentration IP10, MIG, IFNg by enzyme immunoassay. Risk of metastatic colorectal cancer progression after targeted anti-VEGF therapy is determined by formula: K=expz/(1+expz), where K is the probability of disease progression, from 0 to 1, z is regression coefficient z = -8.77+0.011*X1-0.008*X2+0.542*X3, X1 is concentration of cytokine IP10 in pg/ml, X2 is concentration of cytokine MIG in pg/ml, X3 is concentration of cytokine IFNg in pg/ml, -8.77, +0.011, -0.008, +0.542 are coefficients. If K is less than 0.26, the risk of progression is considered to be low. If K is equal to or more than 0.26, the risk of progression is high.

EFFECT: method enables the individual reliable prediction of the risk of progression after the targeted anti-VEGF therapy of metastatic colorectal cancer at the outpatient stage.

1 cl, 2 dwg, 2 ex